NextCure Inc
Company Profile
Business description
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer’s disease.
Contact
9000 Virginia Manor Road
Suite 200
BeltsvilleMD20705
USAT: +1 240 399-4900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
43
Stocks News & Analysis
stocks
Tesla: Shares down despite record deliveries
stocks
ASX listed share dominates their industry
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,240.30 | 42.60 | 0.46% |
| CAC 40 | 8,056.63 | 89.68 | 1.13% |
| DAX 40 | 24,422.56 | 308.94 | 1.28% |
| Dow JONES (US) | 46,533.16 | 92.06 | 0.20% |
| FTSE 100 | 9,427.73 | 18.70 | -0.20% |
| HKSE | 27,287.12 | 431.56 | 1.61% |
| NASDAQ | 22,846.46 | 91.31 | 0.40% |
| Nikkei 225 | 44,936.73 | 385.88 | 0.87% |
| NZX 50 Index | 13,451.76 | 17.77 | 0.13% |
| S&P 500 | 6,717.06 | 5.86 | 0.09% |
| S&P/ASX 200 | 8,945.90 | 40.10 | 0.45% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |